Biohaven (BHVN) GAD Miss a Negative, But Focus on Rimegepant - Mizuho
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $62.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) despite ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
